* Corixa Corp., of Seattle, entered an agreement with London-based SmithKline Beecham plc for development of breast and prostate cancer vaccines based on Corixa's discovery of antigens associated with those diseases. Corixa will receive research funding, milestone payments and royalties. SmithKline will get rights to the antigens and will have options to license Corixa's vaccine technology for other uses. Financial terms were not disclosed.
* IGG International Inc., of Cambridge, Mass., has completed a $2.6 million fundraising effort. Proceeds from the financing will provide the company with the resources to sustain its two lead product development programs well into 1998. GBC-590, for the treatment of cancer metastasis, recently received clearance from the FDA to begin Phase I trials. Additionally, the company submitted to the EPA an application for approval to begin marketing Elexa in the U.S. as a naturally derived agricultural fungicide.
* Immunex Corp., of Seattle, said results of an open-label Phase II study of Leukine (sargramostim) used in association with surgery for treatment of malignant melanoma showed Leukine increased survival rates. The 30 patients participating in the study had a median survival rate of 20.6 months. Leukine, which is a granulocyte macrophage-colony stimulating factor, activates immune system cells. It has been on the market since 1991 for use in restoring white blood cells depleted by cancer chemotherapy.
* Biogen Inc., of Cambridge, Mass., said Avonex for multiple sclerosis received marketing approval by the European Commission. The drug was approved in May 1996 by the FDA. Biogen, which sells Avonex in the U.S., also will market the drug in some European countries, including the U.K., France and Germany. It has European distribution agreements with Schering-Plough Corp., of Madison, N.J., for sales in Spain and Portugal; Astra AB, of Sodertalje, Sweden, for Nordic countries; Dompe SpA, of Milan, for Italy; and Genesis Pharma SA, of Athens, for Greece.
* Lidak Pharmaceuticals Inc., of La Jolla, said preliminary findings from a clinical trial of Lidakol (no-docosanol) showed the topical cream reduced progression and severity of Kaposi's sarcoma skin lesions in AIDS patients.
* NanoSystems LLC, of Collegeville, Pa., entered a collaboration with Astra Draco AB, a research unit of Astra AB, of Sodertalje, Sweden. In the agreement, NanoSystems will apply its drug delivery technology to Astra's products for respiratory disorders. Financial terms were not disclosed.
* ProCyte Corp., of Kirkland, Wash., has received 510(k) device clearance from the FDA to market a gauze wound dressing that contains the company's patented copper peptide technology. The new product, GraftCyte Moist Dressings, will be promoted for use in hair restoration procedures and is scheduled for market release in April 1997.
* Sheffield Medical Technologies Inc., of New York, said it signed a letter of intent to acquire privately held Camelot Pharmacal LLC, of St. Louis, Mo. Financial terms were not disclosed. The acquisition is expected to be complete by the end of May 1997.
* Verigen Inc., of Guilford, Conn., said it began marketing its autologous chondrocyte implants in Denmark, Sweden and Norway through a subsidiary, Verigen Transplantation Services ApS, in Copenhagen, Denmark. The implants are used to treat cartilage defects in knees. Chondrocytes from a patient's healthy cartilage are multiplied in a laboratory and re-implanted to repair the damaged joint.